Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Compugen

Healthcare US CGEN

2.19USD
-0.07(3.10%)

Last update at 2026-06-03T20:00:00Z

Day Range

2.122.24
LowHigh

52 Week Range

1.232.94
LowHigh

Fundamentals

  • Previous Close 2.26
  • Market Cap269.72M
  • Volume807815
  • P/E Ratio7.47
  • Dividend Yield-%
  • EBITDA31.80M
  • Revenue TTM72.76M
  • Revenue Per Share TTM0.78
  • Gross Profit TTM 63.51M
  • Diluted EPS TTM0.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 35.40M -9.70900M -9.78400M -33.63600M -34.20300M
Minority interest - - - - -
Net income 35.34M -14.23100M -18.75400M -33.69400M -32.87300M
Selling general administrative 9.43M 9.44M 9.73M 10.32M 10.86M
Selling and marketing expenses - 0.58M 0.24M 0.93M 0.84M
Gross profit 63.51M 19.93M 31.45M 6.53M 5.32M
Reconciled depreciation 0.47M 0.49M 0.48M 0.48M 0.46M
Ebit 31.33M -14.89100M -12.99200M -35.85600M -35.53500M
Ebitda 31.80M -14.40500M -12.51600M -35.37400M -35.07400M
Depreciation and amortization 0.47M 0.49M 0.48M 0.48M 0.46M
Non operating income net other - - - - -
Operating income 31.33M -14.89100M -12.99200M -35.37400M -35.07400M
Other operating expenses 41.44M 42.76M 46.45M 42.87M 41.07M
Interest expense - 0.03M 0.03M 0.03M 0.87M
Tax provision 0.05M 4.52M 8.97M 0.06M 0.00000M
Interest income 3.90M 3.49M 2.96M 1.74M 0.89M
Net interest income 4.38M 5.20M 3.21M 1.74M 0.87M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M 4.52M 8.97M 0.06M -1.33000M
Total revenue 72.76M 27.86M 33.46M 7.50M 6.00M
Total operating expenses 32.19M 34.83M 44.45M 41.90M 40.39M
Cost of revenue 9.25M 7.93M 2.00M 0.97M 0.68M
Total other income expense net 4.07M 5.18M 3.21M 1.74M 0.87M
Discontinued operations - - - - -
Net income from continuing ops 35.34M -14.23100M -18.75400M -33.69400M -34.20300M
Net income applicable to common shares - - - -33.69400M -34.20300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 156.87M 115.00M 121.33M 94.18M 132.16M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.09M 2.47M 2.21M 72.65M 109.96M
Total liab 54.14M 60.08M 55.77M 16.50M 25.47M
Total stockholder equity 102.73M 54.91M 65.56M 77.68M 106.69M
Deferred long term liab - - - - -
Other current liab 8.73M 8.24M 10.98M 9.53M 11.71M
Common stock 0.26M 0.25M 0.25M 0.24M 0.24M
Capital stock 0.26M 0.25M 0.25M 0.24M 0.24M
Retained earnings -453.41500M -488.75800M -474.52700M -455.77300M -422.07900M
Other liab - - - 3.27M 6.39M
Good will - - - - -
Other assets - - - 4.69M 5.04M
Cash 90.60M 18.23M 14.26M 11.06M 7.80M
Cash and equivalents - - - - -
Total current liabilities 22.57M 20.16M 26.27M 11.92M 17.10M
Current deferred revenue 10.97M 9.63M 11.15M - -
Net debt -87.63700M -15.31700M -12.90400M -9.13400M -5.05100M
Short term debt 0.52M 0.45M 0.63M 0.61M 0.77M
Short long term debt - - - - -
Short long term debt total 2.96M 2.91M 1.35M 1.93M 2.75M
Other stockholder equity 555.88M 543.41M 539.84M 533.21M 528.53M
Property plant equipment - - - 3.36M 3.90M
Total current assets 148.02M 106.00M 114.58M 86.12M 123.22M
Long term investments - - - - -
Net tangible assets - - - 77.68M 106.69M
Short term investments 55.04M 85.03M 36.80M 72.29M 109.25M
Net receivables 0.29M 0.27M 61.32M 2.42M 5.46M
Long term debt - - - - -
Inventory - - - -72.64900M -109.96100M
Accounts payable 2.35M 1.84M 3.50M 1.77M 4.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00800M 0.01M 0.00200M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.94M 5.30M 4.21M 4.69M 5.04M
Deferred long term asset charges - - - - -
Non current assets total 8.85M 9.00M 6.75M 8.05M 8.94M
Capital lease obligations 2.96M 2.91M 1.35M 1.93M 2.75M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 30.32M -46.25200M 35.51M 37.06M 6.91M
Change to liabilities - - - -1.60100M 3.37M
Total cashflows from investing activities 30.00M -46.25200M 35.51M 37.06M 6.62M
Net borrowings - - - - -
Total cash from financing activities 10.60M 0.55M 3.08M 0.35M 16.84M
Change to operating activities - - - -3.95200M 1.45M
Net income 35.34M -14.23100M -18.75400M -33.69400M -34.20300M
Change in cash 72.37M 3.97M 2.83M 2.91M 0.70M
Begin period cash flow 18.23M 14.26M 11.42M 8.51M 7.81M
End period cash flow 90.60M 18.23M 14.26M 11.42M 8.51M
Total cash from operating activities 31.63M 49.60M -35.88600M -34.50600M -22.75000M
Issuance of capital stock 10.54M 0.54M 3.08M 0.00000M 14.96M
Depreciation 0.47M 0.49M 0.48M 0.48M 0.46M
Other cashflows from investing activities - -0.32900M - -0.01000M -0.01000M
Dividends paid - - - - -
Change to inventory - - - - -3.36700M
Change to account receivables 0.36M 59.93M -61.11200M 3.04M 2.00M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.00400M 0.01000M 35.51M 0.35M 1.88M
Change to netincome - - - 4.26M 4.17M
Capital expenditures 0.31M 0.12M 0.17M 0.49M 0.29M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -5.34800M 62.05M -20.70600M -5.55300M 6.82M
Stock based compensation 1.88M 3.02M 3.55M 4.33M 4.28M
Other non cash items 1.16M -1.72400M -0.45200M -0.06900M -0.10400M
Free cash flow 31.33M 49.49M -36.05800M -34.99300M -23.04200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CGEN
Compugen		 -0.07 3.10% 2.19 7.47 12.36 3.71 2.64 1.74 3.98
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen

Azrieli Center, Holon, Israel, 5885849

Key Executives

Name Title Year Born
Dr. Anat Cohen-Dayag Ph.D. CEO, Pres & Director 1967
Dr. Oliver Froescheis Ph.D. Sr. VP of Corp. & Bus. Devel. 1966
Dr. Zurit Levine Sr. VP of Technology Innovation 1968
Dr. Henry Adewoye M.D. Sr. VP & Chief Medical Officer 1965
Mr. Alberto Sessa Chief Financial Officer 1962
Ms. Yvonne Naughton Head of Investor Relations & Corp. Communications NA
Mr. Eran Ben Dor Gen. Counsel & Corp. Sec. NA
Ms. Dorit Amitay VP of HR 1968
Dr. Yaron Turpaz M.B.A., Ph.D., MBA Sr. VP & Sr. Advisor of Computational Discovery 1971
Rivka Schwartz VP Research and Discovery NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.